GlassScriptPhysician profile
Amy Derrick
NPI 1184394991
$372.96
in general payments reported to CMS, 2019-2025
11 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $33.00 · 2024: $75.71 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $159.21 | 2022-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $39.00 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.82 | 2024-2025 | Xifaxan |
| Cipher Pharmaceuticals US LLC | $21.55 | 2025 | Spinosad, Natroba |
| Teva Pharmaceuticals USA, INC. | $18.68 | 2025 | Austedo Xr |
| Lilly USA, LLC | $18.37 | 2024 | Zepbound, Mounjaro |
| Dynavax Technologies Corporation | $17.05 | 2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $16.91 | 2023 | Quviviq |
| Pfizer INC. | $16.09 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.85 | 2022 | |
| Organon LLC | $14.43 | 2025 | Nuvaring, Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Derrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.